Molecular Total Current Liabilities vs Common Stock Analysis
MTEM Stock | USD 0.34 0.04 10.53% |
Molecular Templates financial indicator trend analysis is infinitely more than just investigating Molecular Templates recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Molecular Templates is a good investment. Please check the relationship between Molecular Templates Total Current Liabilities and its Common Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.
Total Current Liabilities vs Common Stock
Total Current Liabilities vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Molecular Templates Total Current Liabilities account and Common Stock. At this time, the significance of the direction appears to have very week relationship.
The correlation between Molecular Templates' Total Current Liabilities and Common Stock is 0.25. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Common Stock in the same time period over historical financial statements of Molecular Templates, assuming nothing else is changed. The correlation between historical values of Molecular Templates' Total Current Liabilities and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Molecular Templates are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Total Current Liabilities i.e., Molecular Templates' Total Current Liabilities and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.25 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Current Liabilities
Total Current Liabilities is an item on Molecular Templates balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Molecular Templates are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Common Stock
Most indicators from Molecular Templates' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Molecular Templates current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.At this time, Molecular Templates' Issuance Of Capital Stock is very stable compared to the past year. As of the 22nd of November 2024, Enterprise Value Over EBITDA is likely to grow to 12.85, while Tax Provision is likely to drop about 18.7 K.
Molecular Templates fundamental ratios Correlations
Click cells to compare fundamentals
Molecular Templates Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Templates fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 174.2M | 139.9M | 192.4M | 97.5M | 35.4M | 33.6M | |
Other Current Liab | 2.5M | 20.4M | 12.1M | 8.8M | 4.3M | 6.7M | |
Total Current Liabilities | 35.8M | 37.6M | 46.7M | 57.1M | 17.3M | 19.2M | |
Total Stockholder Equity | 103.0M | 59.3M | 65.7M | (15.1M) | 4.2M | 4.0M | |
Property Plant And Equipment Net | 28.1M | 33.4M | 27.9M | 25.8M | 16.6M | 17.4M | |
Net Debt | (70.8M) | 1.9M | 20.1M | 18.4M | 707K | 742.4K | |
Retained Earnings | (164.1M) | (269.0M) | (352.1M) | (444.8M) | (452.9M) | (430.2M) | |
Accounts Payable | 1.5M | 2.4M | 1.6M | 504K | 1.5M | 1.3M | |
Cash | 85.5M | 25.2M | 25.0M | 32.2M | 11.5M | 10.9M | |
Non Current Assets Total | 34.3M | 38.6M | 44.1M | 29.3M | 18.6M | 13.4M | |
Non Currrent Assets Other | 4.7M | 5.2M | 7.2M | 3.5M | 142.0K | 134.9K | |
Cash And Short Term Investments | 125.1M | 93.9M | 143.0M | 61.0M | 11.5M | 10.9M | |
Common Stock Shares Outstanding | 2.5M | 3.2M | 3.7M | 3.8M | 4.5M | 4.7M | |
Short Term Investments | 0.0 | 10.2M | 39.6M | 68.7M | 118.1M | 28.9M | |
Liabilities And Stockholders Equity | 174.2M | 139.9M | 192.4M | 97.5M | 35.4M | 33.6M | |
Non Current Liabilities Total | 35.4M | 43.0M | 80.0M | 55.6M | 13.8M | 13.2M | |
Other Current Assets | 489K | 7.2M | 5.2M | 7.2M | 5.0M | 4.0M | |
Other Stockholder Equity | 267.1M | 328.3M | 417.7M | 429.7M | 457.1M | 267.9M | |
Total Liab | 71.2M | 80.5M | 126.7M | 112.7M | 31.2M | 51.2M | |
Property Plant And Equipment Gross | 28.1M | 22.3M | 27.9M | 25.8M | 43.6M | 45.8M | |
Total Current Assets | 139.9M | 101.3M | 148.2M | 68.3M | 16.8M | 15.9M | |
Accumulated Other Comprehensive Income | 18K | 17K | (48K) | (66K) | (75.9K) | (79.7K) | |
Short Long Term Debt Total | 17.5M | 27.1M | 45.1M | 50.6M | 12.2M | 14.4M | |
Current Deferred Revenue | 17.3M | 14.8M | 32.9M | 45.6M | 9.0M | 14.1M | |
Short Term Debt | 14.5M | 2.2M | 2.6M | 2.2M | 2.5M | 2.8M | |
Common Stock Total Equity | 27K | 37K | 46K | 50K | 64.4K | 47.9K | |
Common Stock | 27K | 37K | 46K | 50K | 5K | 4.8K | |
Other Liab | 20.8M | 15.8M | 35.0M | 7.2M | 8.3M | 9.9M | |
Net Tangible Assets | 103.0M | 59.3M | 65.7M | (15.1M) | (17.4M) | (16.5M) | |
Other Assets | 3.5M | 5.2M | 7.2M | 3.5M | 1.0 | 0.95 | |
Long Term Debt | 2.9M | 14.9M | 35.5M | 36.2M | 41.6M | 43.7M | |
Retained Earnings Total Equity | (94.7M) | (164.1M) | (269.0M) | (352.1M) | (404.9M) | (425.1M) | |
Capital Surpluse | 195.6M | 267.1M | 328.3M | 417.7M | 480.4M | 333.7M | |
Deferred Long Term Liab | 2.7M | 19.4M | 4.5M | 33.4M | 30.0M | 19.0M | |
Non Current Liabilities Other | 13.0M | 8.2M | 11.2M | 1.3M | 4.1M | 7.7M | |
Intangible Assets | 1.3M | 1.2M | 1.1M | 700K | 600K | 570K | |
Property Plant Equipment | 18.2M | 33.4M | 19.3M | 25.8M | 29.6M | 31.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Templates. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Templates listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (3.05) | Revenue Per Share 4.544 | Quarterly Revenue Growth (0.92) | Return On Assets (0.38) |
The market value of Molecular Templates is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Templates' value that differs from its market value or its book value, called intrinsic value, which is Molecular Templates' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Templates' market value can be influenced by many factors that don't directly affect Molecular Templates' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Templates' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Templates is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Templates' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.